The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete. | |||||||||||||||||
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 13F FORM 13F INFORMATION TABLE |
|
COLUMN 1 | COLUMN 2 | COLUMN 3 | COLUMN 4 | COLUMN 5 | COLUMN 6 | COLUMN 7 | COLUMN 8 | ||||
VALUE | SHRS OR | SH/ | PUT/ | INVESTMENT | OTHER | VOTING AUTHORITY | |||||
NAME OF ISSUER | TITLE OF CLASS | CUSIP | (x$1000) | PRN AMT | PRN | CALL | DISCRETION | MANAGER | SOLE | SHARED | NONE |
JUNO THERAPEUTICS, INC. | COM | 48205A109 | 83,627 | 1,864,174 | SH | OTR | 1,764,790 | 99,384 | 0 | ||
MABVAX THERAPEUTICS HOLDINGS, INC. | COM NEW | 55414P504 | 17 | 26,708 | SH | OTR | 26,708 | 0 | 0 | ||
ADMA BIOLOGICS, INC. | COM | 000899104 | 4,415 | 1,433,304 | SH | OTR | 1,433,304 | 0 | 0 |